Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

Background: Approximately 164,000 deaths yearly are due to shigellosis, primarily in developing countries. Thus, a safe and affordable Shigella vaccine is an important public health priority. The GSK Vaccines Institute for Global Health (GVGH) developed a candidate Shigella sonnei vaccine (1790GAHB)...

Full description

Bibliographic Details
Main Authors: Odile Launay, David J.M. Lewis, Alessandra Anemona, Pierre Loulergue, Jo Leahy, Antonella Silvia Sciré, Anaïs Maugard, Elisa Marchetti, Stefano Zancan, Zhiming Huo, Simona Rondini, Rachid Marhaba, Oretta Finco, Laura B. Martin, Jochen Auerbach, Daniel Cohen, Allan Saul, Christiane Gerke, Audino Podda
Format: Article
Language:English
Published: Elsevier 2017-08-01
Series:EBioMedicine
Subjects:
Shigella sonnei
Vaccine
Clinical study
GMMA
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396417302864

Internet

http://www.sciencedirect.com/science/article/pii/S2352396417302864

Similar Items